| Description |
1 online resource (297 p.) |
| Contents |
Front Cover -- Protein Biosynthesis Interference in Disease -- Copyright Page -- Contents -- Preface -- 1 Introduction -- 2 Tryptamine in the diet, human microbiome, tRNA aminoacylation-protein biosynthesis, host-microbiota metabolic interactions -- 2.1 Tryptamine interfere with the tRNA aminoacylation-protein biosynthesis in the model of neurodegeneration -- 2.2 Tryptamine interfere with serotonin binding to receptors in serotonin syndrome -- 2.3 Tryptamine in dysbiosis -- 3 Dimethyltryptamine, methyltryptamine, hallucinations and metals |
|
4 Psychoactive effects and toxicity of tryptamine, N-methyltryptamine (NMT), and N, N-dimethyltryptamine (DMT): quantificat... -- 5 Tryptamine in renal pathologies and in pregnancy -- 6 Tryptophanyl-tRNA synthetase (TrpRS) inhibition or TrpRS gene (WARS) mutations and deletion result to TrpRS deficiency an... -- 7 Tryptamine in liver diseases and alcohol abuse -- 8 Tryptamine and tyramine in tobacco smoking -- 9 Tryptamine and other biogenic amines in human vaginal samples -- 10 Tryptamine and tryptophan in human fecal samples: diet alters tryptamine levels |
|
11 Tryptamine in human noncataractous and cataractous eye lenses -- 12 Tryptamine toxicity in rats, adrenalectomy, toxicity prevention -- 13 Microorganisms: the natural producers of tryptamine in food -- 14 Human gut bacterial sequence associated with Alzheimer's disease and biogenic amines -- 15 Diseases, factors and conditions associated with Alzheimer's disease (AD) and dementia support a concept that AD is a wi... -- 15.1 Historical evolution and terminology from 1907 to contemporary -- 15.2 Senile plaques and neurofibrillary tangles in organs other than brain |
|
15.3 Diseases, factors and conditions associated with Alzheimer's disease and dementia -- 16 Arterial hypertension is comorbidity in dementia and Alzheimer's disease, tryptamine in metabolic syndrome -- 17 Whole blood viscosity: biogenic amines, dementia and Alzheimer's disease -- 18 Tryptamine and aminoacyl-tRNAs in sleep-wake and circadian disruption -- 19 Senile plaques and/or neurofibrillary tangles in brain of non-demented individuals -- 20 Historical perspective and future research directions |
|
20.1 On determining the most appropriate test cut-off values for Alzheimer's disease associated sequence (ADAS)-linked tryp... -- 20.2 Updated hypothesis of tryptamine-induced neurodegeneration: experimental and observational data -- 20.3 Validation studies and future experiments -- 20.4 Major challenges for new preclinical and clinical trials -- 20.5 Tryptamine physiological pathways: tryptamine is a ligand and agonist activating 5H, TAAR1, and AhR receptors -- 20.6 Linkage of present theory to other theories and the major pathological features of Alzheimer's disease |
| Notes |
Description based upon print version of record |
|
21 Tryptamine content and effects in human and animals |
| Form |
Electronic book
|
| ISBN |
9780128234860 |
|
0128234865 |
|
